Disclosure: Lynn Webster, MD, has received funding from the following companies as compensation for clinical research or as honoraria: Adolor, Alkermes, Allergan, AlphaBioCom, American Academy of Pain Medicine, American Board of Pain Medicine, AstraZeneca, Bayer, BioDelivery Sciences International, Boston Scientific, Cephalon, Collegium Pharmaceuticals, Covidien, Eisai, Elan Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Identigene (Sorenson), King Pharmaceuticals, Meagan Medical, Medtronic, Merck, Naurex, Nektar Therapeutics, NeurogesX, Nevro Corporation, Novartis, Pfizer, SchaBar, Shionogi USA, St. Renatus, SuCampo Pharma Americas, Takeda, TEVA Pharmaceuticals, Theravance, Vanda, Vertex, and Xanodyne Pharmaceuticals.
Review and Critique of Opioid Rotation Practices and Associated Risks of Toxicity
Version of Record online: 28 MAR 2012
Wiley Periodicals, Inc.
Volume 13, Issue 4, pages 562–570, April 2012
How to Cite
Webster, L. R. and Fine, P. G. (2012), Review and Critique of Opioid Rotation Practices and Associated Risks of Toxicity. Pain Medicine, 13: 562–570. doi: 10.1111/j.1526-4637.2012.01357.x
Perry Fine, MD, over the last 12 months has received honoraria for serving on advisory boards for Ameritox, Archimedes, Nuvo, Covidien, Purdue Pharma, and Pricara/OrthoMcNeil, and he has received consulting fees for medical-legal consultation for Johnson & Johnson, Cephalon, and Mylan.
- Issue online: 12 APR 2012
- Version of Record online: 28 MAR 2012
Vol. 13, Issue 12, 1667, Version of Record online: 17 DEC 2012
- Opioid Rotation;
- Equianalgesic Dose Tables;
- Opioid Dose Conversion
Objectives. A dramatic increase in unintentional deaths from opioids has occurred over the past decade with strong inference that many of these deaths may be resulting from prescriber's error. Recent evidence suggests that the use of dose conversion ratios published in equianalgesic tables may lead to fatal or near-fatal opioid overdoses. The objective of this review was to determine whether the current practice of opioid rotation may be contributing to high rate of unintentional deaths.
Methods. We performed a focused literature review to identify reports of fatal or near-fatal outcomes that have occurred in conjunction with opioid rotation, to evaluate clinician competence in opioid rotation, and to identify inconsistencies in published protocols for opioid rotation. Further information was obtained by reviewing dosing instructions contained in product labels for extended-release formulations of several opioids.
Results. An increasing body of literature suggests that widely used opioid rotation practices, including the use of dose conversion ratios found in equianalgesic tables, may be an important contributor to the increasing incidence of opioid-related fatalities. These errors may be due, in part, not only to inadequate prescriber's competence but also to proliferation of inconsistent guidelines for opioid rotation, conflation of equianalgesic tables as conversion tables, and limitations inherent in the equianalgesic dose tables.
Conclusions. Most of the fatal outcomes occurring during opioid rotation are preventable. The current process being used for opioid rotation has important flaws that must be corrected.